United Orthopedic Corporation (UOC) commenced 200-patient enrollment in a U.S. follow-up study of the U-Motion II+ Acetabular System and UTF Reduced Stem in primary total hip arthroplasty (THA) patients.
The prospective, single arm, 5-site, post-approval study is investigating short- and long-term clinical performance of the devices, which are designed to improve hip flexion, reduce the risk of joint dislocation and allow for minimal bone removal during THA. The study is slated to require ~7 years from 1st enrollment through final report.
Number of THA surgeries among inpatients aged 45+ more than doubled from 2000 to 2010: from 138,700 in 2000 to 310,800 in 2010
Percentage increase in the number of THAs among inpatients aged 45+ by age ranged from 92% for those 75+, to 205% for those aged 45–54
United Orthopedic Corporation (UOC) commenced 200-patient enrollment in a U.S. follow-up study of the U-Motion II+ Acetabular System and UTF Reduced Stem in primary total hip arthroplasty (THA) patients.
The prospective, single arm, 5-site, post-approval study is investigating short- and long-term clinical performance of the devices, which are...
United Orthopedic Corporation (UOC) commenced 200-patient enrollment in a U.S. follow-up study of the U-Motion II+ Acetabular System and UTF Reduced Stem in primary total hip arthroplasty (THA) patients.
The prospective, single arm, 5-site, post-approval study is investigating short- and long-term clinical performance of the devices, which are designed to improve hip flexion, reduce the risk of joint dislocation and allow for minimal bone removal during THA. The study is slated to require ~7 years from 1st enrollment through final report.
Copy to clipboard 
